Experts have warned that amidst milder and milder variants, vaccines might not be needed in the future.
After more and more reports reveal Omicron is milder than previous variants like Delta, experts have said that future variants could act as a “natural vaccine”.
This comes as Israel have announced intentions to begin offering a fourth jab to people, which acts as a second round of booster jabs.
Professor Ian Jones, a virologist at the University of Reading, told MailOnline that after Omicron, future variants “may be even more mild”.
He argued this means they could act as a “natural vaccine” as lots of people would get infected without suffering severe illness or death.
This could mean the need for adults to get regular booster jabs could recede over time.
Other scientists have spoken out questioning whether the country will see regular Covid boosters.
Dr Simon Clarke, a microbiologist at the University of Reading, said he “couldn’t see” ministers giving out boosters every few months.
He said: “Although after two-and-a-half months immunity starts to wane, that doesn't mean it drops below being extremely effective.”
He added that the only way to measure the long-term effectiveness of the boosters was to wait and see.
Other epidemiologists have said that repeated outbreaks of Covid every year could mean boosters are needed every four to six months.
Early real-world analysis of the UK’s booster programme has shown that Pfizer’s top-up dose efficacy drops down as low as 35 per cent after two-and-a-half months.
This was among people who had already had a two doses of AstraZeneca.
But, amongst people who had two shots of Pfizer, and then a Moderna booster, efficacy remains stable around 70 per cent after the same period of time.
People who had had a third Pfizer, after two previous jabs, saw their protection drop to the 45 per cent region.
Britain is considering fourth jabs but it would mean the NHS dishing out tens of millions of boosters roughly every 100 days.
Pfizer jabs cost around £20, meaning each annual vaccination drive would be in the region of £4billion.
However, two jabs still do drastically reduce the risk of hospitalisation and death, even against Omicron.
And a third booster only improves that protection.
There is concern as well about giving fourth jabs to people who already have considerable protection when outside richer economies much of the world is still waiting on first jabs.
